Medizinische Universität Graz - Research portal
Schaberl-Moser Renate |
Presentations at scientific and public conferences
Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Riedl, J; Posch, F; Stotz, M; Bezan, A; Winder, T; Schaberl-Moser, R; Pichler, M; Stoeger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
Annals of Oncology. 2016; -ESMO congress; Oct 7-11; Copenhagen.
[Poster]
Riedl, J; Posch, F; Stotz, M; Bezan, A; Winder, T; Schaberl-Moser, R; Pichler, M; Stoeger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.107
[Poster]
Web of Science
FullText
FullText_MUG
Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Langle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.41
[Poster]
Web of Science
FullText
FullText_MUG
Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Längle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
Annals of Oncology. 2016; -ESMO congress; Oct 7-11; Copenhagen.
[Poster]
Stotz, M; Herzog, SA; Pichler, M; Szkandera, J; Schaberl-Moser, R; Samonigg, H; Renner, W; Berghold, A; Gerger, A;
Cancer stem cell gene variants and colon cancer prognosis.
Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie; April 23-25, 2015; Salzburg. 2015.
[Poster]
Stotz, M; Pichler, M; Bezan, A; Peinsith, H; Szkandera, J; Arminger, F; Schaberl-Moser, R; Samonigg, H; Stojakovic, T; Gerger, A
The preoperative C-reactive protein (CRP) and fibrinogen level predicts clinical outcome in patients with stage III colon cancer
Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie; April 10-12, 2014; Innsbruck. 2014.
[Poster]
Heitzer E, Mach M, Filipits M, Balic M, Resel M, Graf R, Weißenbacher B, Lax S, Heitzer, E; Mach, M; Filipits, M; Balic, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Samonigg, H; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Schaberl-Moser, R; Dandachi, N.
Methylation of PCDH10, SPARC, and UCHL1 predicts survival and in stage II colorectal cancer patients.
http://gfhev.de/de/kongress/GfH_Tagung_2013_Abstractbook.pdf. 2013; -24. Jahrestagung der Deutschen Gesellschaft für Humangenetik ; MAR 20-22,2013; Dresden, GERMANY.
[Poster]
Eisner, F; Pichler, M; Gerger, A; Schaberl-Moser, R; Samonigg, H
49 Monate Progressions-freies Überleben bei einem Patienten mit metastasiertem Kolonkarzinom unter Avastin- Erhaltungstherapie Ein Fallbericht
Frühjahrstagung der Österreichischen Gesellschaft für Hämtologie und Onkologie; APR 12-14, 2012; Graz, Austria. 2012.
[Poster]
Eisner, F; Schaberl-Moser, R; Pichler, M; Samonigg, H
The multi-kinase inhibitor sorafenib in metastatic follicular thyroid cancer a case report
Frühjahrstagung der Österreichischen Gesellschaft für Hämatlogie und Onkologie; APR 12-14, 2012; Graz, Austria. 2012.
[Poster]
Heitzer, E; Marija, B; Resel, M; Graf, R; Weissenbacher, B; Schaberl-Moser, R; Dandachi, N;
IDENTIFICATION OF PROGNOSTIC METHYLATION MARKERS IN PATIENTS WITH EARLY STAGE COLORECTAL CANCER.
ANN ONCOL. 2012; 23: 87-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
Thalhammer, M; Kohek, P; Suppan, C; Lackner, K; Schaberl-Moser, R; Schoellnast, H; Werkgartner, G; Mischinger, H
Benefit of chemotherapy in patients with ductal adenocarcinoma of the pancreas with vascular infiltration.
ANN ONCOL. 2011; 22: v61-v61.-World Congress on Gastrointestinal Cancer (WCGIC); JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
Komek, G; Schueller, J; Schaberl-Moser, R; Keil, F; Andel, J; Renner, F; Eisterer, W; Balcke, P; Scheithauer, W
LIMITED TREATMENT DURATION & RE-INDUCTION OF THE SAME REGIMEN UPON PROGRESSION VERSUS TREATMENT UNTIL PROGRESSION WITH XELOX plus BEVACIZUMAB IN PATIENTS WITH ADVANCED COLORECTAL CANCER
ANN ONCOL. 2009; 20: 62-62.
[Poster]
Web of Science
Resch, G; Schaberl-Moser, R; Kier, P; Kopetzky, G; Scheithauer, W; Sliwa, T; Greil, R; Nösslinger, B; Mayrbäurl, T; Thaler J;
Analysis of the Austrian compassionate use program of panitumumab (pmab) in patients (pts) with metastatic colorectal cancer (mCRC)
Gastrointestinal Cancers Symposium (ASCO-GI); Jänner 2009; Orlando. 2009.
[Poster]
Douillard, J; Rolski, J; Barone, C; Schaberl-Moser, R; Eggleton, SP
CAN UFT REPLACE INFUSIONAL 5-FU IN COMBINATION THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)? PRELIMINARY RESULTS OF THE RANDOMISED FUTURE'' STUDY
ANN ONCOL. 2008; 19: 134-134.-33rd European-Society-for-Medical-Oncology Congress; SEP 12-16, 2008; Stockholm, SWEDEN.
[Poster]
Web of Science
Rolski, J; Barone, C; Schaberl-Moser, R; Eggleton, S; Douillard, J
Randomized trial of either UFT or infusional 5-FU in combination with Erbitux, oxaliplatin and folinic acid in first-line treatment of metastatic colorectal cancer
ANN ONCOL. 2008; 19: 27-28.
Web of Science
Schaberl-Moser, R
Functional Imaging of Biological Tumour Attributes Clinical Significance -Oncologists Point of view
Annual Meeting of the Austrian Society for Medical Physics (ÖGMP) and 3rd Austrian, Italian, Slovenian an Croatian Medical Physics Meeting; MAY 30-31, 2008; Graz . 2008.
[Oral Communication]
Schaberl-Moser, R
Kolorektales Karzinom - Bevacizumab bis zur Progression - Falldiskussion
Vortragsabnd: Modernes Management des metastasierten Kolorektalkarzionoms ; FEB, 2008; Wien. 2008.
[Oral Communication]
Schaberl-Moser, R
Magenkarzinom - State of the Art 2008
Kliniknachmittag; FEB, 2008; Univ. Klinik für Innere Medizin. 2008.
[Keynote lecture]
Schaberl-Moser, R
Intraarterielle Chemotherapie - Mehr Möglichkeiten durch breiteres Spektrum
Wissenschaftliches Symposium: Chemoemolistation von inoperablen primären und sekundären Leberkarzinom; JAN 21, 2008; Univ. Klinik für Innere Medizin, HS D. 2008.
[Oral Communication]
Schaberl-Moser, R
Kolorektales Karzinom - Stellenwert der medikamentösen Therapie.
Internisten, 2008; -Expertenkommentar zu ASCO 2008 Abstracts; ; .
[Poster]
Schaber-Moser, R
Adjuvante Chemotherapie beim Kolonkarzinom
25. Jahrestagung ACO-ASSO St. Wolfgang, 99. Fortbildungsverastaltung der ÖGCH; OCT 8-9, 2008; St. Wolfgang. 2008.
[Oral Communication]
Scheithauer, W; Kornek, G; Aigner, K; Schaberl-Moser, R; Keil, F; Andel, J; Renner, F; Eisterer, W; Balcke, P; Schuller, J
LIMITED TREATMENT DURATION AND RE-INDUCTION WITH THE SAME REGIMEN ON PROGRESSION VS TREATMENT UNTIL PROGRESSION WITH BIWEEKLY CAPECITABINE plus OXALIPLATIN +/- BEVACIZUMAB IN PATIENTS (PTS) WITH ADVANCED COLORECTAL CANCER (CRC): A RANDOMISED PHASE II STUDY
ANN ONCOL. 2008; 19: 169-169.-33rd European-Society-for-Medical-Oncology Congress; SEP 12-16, 2008; Stockholm, SWEDEN.
[Poster]
Web of Science
Scheithauer, W; Kornek, G; Aigner, K; Schaberl-Moser, R; Keil, F; Andel, J; Renner, F; Eisterer, W; Balcke, P; Schüller, J;
Limited treatment duration and re-induction with the same regimen on progression vs treatment until progression with biweekly capecitabine + oxaliplatin +/- bevacizumab in patients with advanced colorectal cancer (CRC): A randomized phase II study.
Annals of Oncology 2008 Sep; 19 (Suppl 8), 514 PD2008; -33rd ESMO Congress ; Sep 12-16, 2008; Stockholm, Schweden.
[Poster]
Samonigg, H; Andritsch, E; Dietmaier, G; Bauernhofer, T; Andritsch, H; Zloklikovits, S; Kasparek, AK; Stoeger, H; Schaberl-Moser, R; Ploner, F
Healing by Design: the Influence of an Artistic Design on the Wellbeing of Cancer Patients-- a 10 Years Follow Up.
Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part I. (June 20 Supplement); 24(18S):-2006 ASCO Annual Meeting; JUNE 2-6, 2006; Atlanta, USA.
[Poster]
Schaberl-Moser, R
Multimodale Therapie des Pankreaskarzinoms
; 2006.
[Oral Communication]
Wagner P, Schaberl-Moser R, Langsenlehner U, Stranzl H, Gabor S, Samonigg H
Postoperative chemoradiation therapy in patients with esophageal cancer- A pilot study
Wiener Med Wochenschrift2005; 117: 14--ÖGHO; 28.-29. April 2005; Graz.
[Poster]